MedTrace Logo

Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study

NCT06486779 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2025-12-24

No results posted yet for this study

Summary

This study is a single-country, non-interventional, multicenter, observational study, mainly based on primary data collection to assess the effect of ofatumumab on clinical parameters of Multiple Sclerosis (MS) in a routine medical care setting, as compared to the standard of care (SoC) arm of a closely monitored phase-IIIb study (STHENOS, which includes glatiramer acetate, interferons, teriflunomide, or dimethyl fumarate)

Conditions

  • Relapsing Multiple Sclerosis (RMS)

Interventions

OTHER

Ofatumumab

This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-10
Primary Completion
2028-12-30
Completion
2028-12-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06486779 on ClinicalTrials.gov